<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is a common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> with a high incidence and mortality rate </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have pointed to deregulation of autophagy as a novel pathogenesis of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>SM22 is considered as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the present study was to evaluate the correlation of the SM22 expression level with the autophagy activity and the clinical characteristics in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues </plain></SENT>
<SENT sid="4" pm="."><plain>The expressions of SM22 and p62, a biomarker of autophagy activity, in paired <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and adjacent non-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues from 43 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> were detected by western blot and immunohistochemical staining, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The results showed that the SM22 level decreased significantly in 81.4% <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues, while the expression of p62 increased in 79.1% cases </plain></SENT>
<SENT sid="6" pm="."><plain>There was a negative correlation between p62 and SM22 expressions in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissues (p=0.004) </plain></SENT>
<SENT sid="7" pm="."><plain>Similarly, the negative correlation between SM22 and p62 was verified in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="8" pm="."><plain>The data suggest that the autophagy activity decreased in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, which was associated with reduction in SM22 expression </plain></SENT>
<SENT sid="9" pm="."><plain>However, the expression of SM22 was not associated with the gender, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site and Duke's stage of the patients </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, our findings suggest that the disruption of SM22 may be involved in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The autophagic activity may be suppressed in human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and SM22 may act as a positive regulator in the processes of autophagy </plain></SENT>
</text></document>